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Abstract
Background: Curcumin is a polyphenolic compound isolated from the rhizomes of the plant Curcuma longa and
shows intrinsic anti-cancer properties. Its medical use remains limited due to its extremely low water solubility and
bioavailability. Addressing this problem, drug delivery systems accompanied by nanoparticle technology have
emerged. The present study introduces a novel nanocarrier system, so-called CurcuEmulsomes, where curcumin is
encapsulated inside the solid core of emulsomes.
Results: CurcuEmulsomes are spherical solid nanoparticles with an average size of 286 nm and a zeta potential of
37 mV. Encapsulation increases the bioavailability of curcumin by up to 10,000 fold corresponding to a
concentration of 0.11 mg/mL. Uptaken by HepG2 human liver carcinoma cell line, CurcuEmulsomes show a
significantly prolonged biological activity and demonstrated therapeutic efficacy comparable to free curcumin
against HepG2 in vitro - with a delay in response, as assessed by cell viability, apoptosis and cell cycle studies. The
delay is attributed to the solid character of the nanocarrier prolonging the release of curcumin inside the HepG2
cells.
Conclusions: Incorporation of curcumin into emulsomes results in water-soluble and stable CurcuEmulsome
nanoformulations. CurcuEmulsomes do not only successfully facilitate the delivery of curcumin into the cell
in vitro, but also enable curcumin to reach its effective concentrations inside the cell. The enhanced solubility of
curcumin and the promising in vitro efficacy of CurcuEmulsomes highlight the potential of the system for the
delivery of lipophilic drugs. Moreover, high degree of compatibility, prolonged release profile and tailoring properties
feature CurcuEmulsomes for further therapeutic applications in vivo.
Keywords: Curcumin, Emulsome, Nanocarrier, Lipophilic drug, Cell cycle arrest, Drug delivery, Enhanced solubility,
Prolonged release, Nanoformulation
Background
Curcumin, chemically known as diferuloyl methane, is a
hydrophobic polyphenol derived from the rhizome of
the plant Curcuma longa (turmeric) of the Zingiberaceae
family. Curcumin is known to suppress multiple signal-
ing pathways and inhibit cell proliferation, invasion,
metastasis and angiogenesis [1]. Its wide medical use
includes anti-septic, analgesic, anti-inflammatory, anti-
oxidant, anti-malarial and wound-healing [2]. In recent
years, a particular interest was shown on the anti-
oxidative and anti-inflammatory properties of curcumin
which might provide a therapeutic window for cancer
treatment [3].
Curcumin is a yellow-colored tautomeric compound
that is quite soluble in organic solvents such as dimethoxy
sulfoxide (DMSO), ethanol, methanol, chloroform or acet-
one. Upon dissolution in an organic solvent, curcumin ab-
sorbs light in the visible wavelength range [4]. Turmeric
contains three major analogues: curcumin, demethoxycur-
cumin (DMC), and bisdemethoxycurcumin (BDMC)
and recently identified cyclocurcumin in less signifi-
cant amounts [5]. Commercially available curcumin mix-
ture contains approximately 77% curcumin, 17% DMC
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and 3% BDMC as major components [6]. Although all
three are highly active, curcumin is more efficient than
DMC and BDMC on various cell models [6,7]. Con-
trary to these findings, studies on preclinical models of
carcinogenesis have demonstrated that commercial
grade curcumin – turmeric as a mixture - has the same
inhibitory effect as pure curcumin [8,9].
Pharmacologically regarded as safe, curcumin is non-
toxic, even at relatively high doses [10] such as 8 g per
day [11]. As demonstrated recently, tumor cells are more
sensitive to the cytotoxic activity of curcumin than nor-
mal cells [12]. In line with another study, the cellular up-
take of curcumin was found to be significantly higher in
tumor cells compared to normal cells, which was attrib-
uted to the differentiated membrane structure, protein
composition and bigger size [13]. The lower uptake rate
may explain the low toxicity of curcumin for healthy
cells.
The wide spectrum of pharmacological properties of
curcumin is attributed to its numerous effects on several
targets including transcription factors, growth regula-
tors, adhesion molecules, apoptotic genes, angiogenesis
regulators, and cellular signaling molecules [14]. Curcu-
min exerts anti-cancer activity mainly through blocking
cell cycle progression and triggering tumor cell apoptosis
[15]. All three stages of carcinogenesis including initi-
ation, promotion and progression are suppressed by cur-
cumin [16]. This is probably due to inhibition of the
nuclear factor κB, which plays a central role in regulat-
ing the expression of various genes involved in cell sur-
vival, apoptosis, carcinogenesis and inflammation. This
efficacy makes curcumin to a potential therapeutic target
[17]. Furthermore, curcumin affects various cell cycle
proteins and checkpoints involving downregulation of
some of the cyclins and cyclin-dependent kinases (cdk),
upregulation of cdk inhibitors, and inhibition of DNA syn-
thesis [18]. However, the physiological response triggered
by curcumin depends on the cell type, the concentration
of curcumin (IC50: 2-40 μg/ml) and the time of treatment
[19]. For instance, curcumin treatment was reported to ar-
rest cell growth at G2/M phase and induce apoptosis in
human hepatoma cell line HepG2 [20,21], whereas G0/G1
as well as G1/S phase arrests were reported for various
other cell lines [18].
Clinical use of curcumin remains very limited due to
its extremely poor water solubility (≈11 ng/ml) [22], and
low bioavailability following oral administration [23].
Even when 10-12 g/ml of curcumin was administered
orally in humans, curcumin levels in serum remained
approximately at 50 ng/ml [24]. Several studies demon-
strated that 10-50 μM (3.7-18.4 μg/ml) curcumin in-
duces cell death primarily through apoptosis [25,26].
However, the important question to be addressed is how
to bring curcumin at these micromolar concentrations
to the site of tumors while curcumin possesses such a
low bioavailability. Addressing this problem, targeted
and triggered drug delivery systems accompanied by
nanoparticle technology have emerged as prominent so-
lutions [23]. Likewise, this study introduces emulsomes
as a promising nanocarrier system suitable for the deliv-
ery of curcumin.
Emulsomes are biocompatible vesicular systems com-
prising of a solid fat core surrounded by phospholipid
multi-layers (Figure 1) [27]. Due to the solid core, emul-
somes can entrap higher amounts of lipophilic drug
compounds with a prolonged release time compared to
emulsion formulations possessing a liquid core [27-29].
Composed of fat and lipids, emulsomes are biocompat-
ible. These characteristic properties make emulsomes to
promising candidates for poorly water-soluble thera-
peutic agents such as curcumin.
As recently demonstrated, the assembly of phospho-
lipids and triglycerides to form a stable dispersed emul-
somes can be prepared by a dehydration-rehydration
Figure 1 Schematic drawing of CurcuEmulsome. CurcuEmulsome is composed of a solid tripalmitin core surrounded by phospholipid
multi-layers. The lipophilic load, i.e. curcumin, can locate itself in the inner core, as well as inside the phospholipid layers of the nanocarrier.
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process followed by temperature-controlled extrusion
[30]. In the present study, curcumin-emulsome nanofor-
mulations, or so-called CurcuEmulsomes, were formu-
lated using the same methodology, and characterized
with respect to their structural and biophysical proper-
ties. HepG2 cell line was used as the in vitro cellular
model to study cellular uptake of CurcuEmulsomes and
to evaluate the biological effects of the incorporated cur-
cumin on cellular morphology, as well as viability, com-
pared to its free form. Cell cycle studies were performed
to study CurcuEmulsome's effect on cell proliferation
and implicitly to verify the incident of prolonged release
of curcumin in biological level.
Results
CurcuEmulsome nanoformulation
The structural design of CurcuEmulsomes enables cur-
cumin to be localized in the inner solid tripalmitin core,
as well as inside the phospholipid layers surrounding
and stabilizing the nanocarrier (Figure 1). In contrast to
free curcumin, poorly soluble in water (Figure 2A), cur-
cumin incorporated into CurcuEmulsomes is a colloidal
solution (Figure 2B). Forming an intensive turbid sus-
pension, CurcuEmulsomes achieved curcumin concen-
trations up to 0.11 mg/ml (in range of 0.07-0.11 mg/ml)
as estimated by absorbance measurements, where the
latter value corresponds to a 10,000-fold increase in
solubility of curcumin (i.e. ≈11 ng/ml [22]).
The aforementioned values correspond to the concen-
trations of curcumin incorporated into CurcuEmul-
somes, as unincorporated curcumin in the solution was
already spin down after a centrifugation process. Spin-
down resulted in recovery of incorporated curcumin –
corresponding to 90% of total - within the supernatant
containing CurcuEmulsomes, indicating that a stable in-
corporation was achieved.
Particular characterization of CurcuEmulsomes
TEM micrographs verified that CurcuEmulsomes are
spherical in shape, and hence, similar in size and morph-
ology to empty emulsomes (Figure 3A). DLS analysis
with Zetasizer Nano ZS (Malvern Instruments Ltd, UK)
determined the average diameter of ten distinct CurcuE-
mulsome formulations as 286 ± 27 nm (polydispersity
index of 0.34; conductivity of 0.17 ± 0.01 mS/cm) -
where the plus-minus sign indicates the margin of aver-
age size of numerous CurcuEmulsome formulations
made of the same composition. Consistent with this
value, the mean diameter of empty emulsomes was pre-
viously reported to be 297 ± 28 nm [30]. In addition, zeta
potential of CurcuEmulsomes (37 ± 8 mV) is comparable
to that of empty emulsomes (37 ± 7 mV) [30]. With
the aid of the auto-fluorescence properties of curcu-
min, it was possible to evidence the incorporation of
curcumin into emulsomes and that the prepared nano-
carrier system is a stable dispersed formulation in
water (Figure 3B). Consequently, the presented data
declines any significant influence of incorporated drug
neither on the size nor on the surface potential of the
nanocarrier, which could further affect the particular
dispersity of the nanocarrier in water.
Tautomeric curcumin incorporated into CurcuEmulsomes
in its enol form
Curcumin is a yellow-colored tautomeric compound that,
upon dissolution in an organic solvent, absorbs light in the
visible wavelength range [4]. In nonpolar, i.e. aprotic sol-
vents such as chloroform, the spectrum displays vibronic
Figure 2 Enhanced solubility. (A) Free curcumin is poorly soluble in water and macroscopic flakes are visible especially on the top and the
bottom of the bottle. (B) Curcumin incorporated into CurcuEmulsomes, in contrast, is homogeneously dispersed in water.
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structure with λmax near 420 nm. This feature corresponds
to the fully conjugated form of the protonated enol [31]. In
polar protic solvents such as DMSO, the vibronic features
are no longer resolved, and hence, the molar absorptivity
decreases as solvent polarity increases resulting in λmax
shifts to nearly 430 nm [31]. In agreement with this
[4,32,33], the UV–vis spectrum of CurcuEmulsomes dis-
played the same λmax as curcumin in chloroform (420 nm),
and differed from λmax of curcumin dissolved in DMSO
(Figure 4A). Hence, curcumin incorporated in CurcuEmul-
somes is evidently in its fully conjugated protonated enol
form.
Like the absorbance spectrum, the emission spectrum of
CurcuEmulsomes pursued that of curcumin in chloroform
and showed a λmax at 500 nm (Figure 4B). Excitated at
420 nm, free curcumin in DMSO showed an emission
peak centered at 520 nm and curcumin in water did not
fluoresce.
Curcumin composition inside CurcuEmulsomes
Since turmeric as a mixture was demonstrated to have
the same inhibitory effect as pure curcumin [8,9], curcu-
min was used as purchased without any further purifica-
tion. Therefore, the turmeric fed to the system contained
all three analogues, i.e. curcumin, DMC and BDMC.
HPLC analysis showed that the turmeric extract consisted
of 78.1% curcumin, 17.7% DMC and 4.1% BDMC
(Figure 5A), whereas CurcuEmulsomes comprised of
40.8% curcumin, 40.3% DMC and 16.8% BDMC (Figure 5B).
As curcumin analogues were the only substances in Cur-
cuEmulsomes raising a peak at 420 nm, empty emulsomes
did not show any peak in HPLC analysis (Figure 5C).
Effect of CurcuEmulsomes on HepG2 cell viability
Previous studies demonstrated that 10–50 μM curcumin
induces cell death primarily through apoptosis [25]. Within
this range, HepG2 cells were treated with CurcuEmulsomes
Figure 3 Particular analysis of CurcuEmulsomes. A) Transmission electron micrograph demonstrates CurcuEmulsomes are spherical in shape
and have a diameter in range of 50–350 nm. B) Fluorescence microscopy image does not only confirm the incorporation of curcumin into
CurcuEmulsomes, but also verifies the high-level dispersity of CurcuEmulsomes in water. Bars correspond to 500 nm and 2 μm, respectively.
Figure 4 Spectral analysis of CurcuEmulsomes. (A) UV–vis absorbance spectra (excitation wavelength: 420 nm) and (B) emission spectra of
curcumin in various forms: (i) curcumin in DMSO (red), (ii) curcumin in chloroform (green), (iii) curcuemulsomes in water (1:100 diluted) (yellow),
and (iv) curcumin in water (blue).
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and free curcumin (in DMSO) of the same concentrations,
respectively. After treatment for 6, 24 and 48 hours, the cell
viability was determined with CellTiter-Blue assay. As
shown in Figure 6, CurcuEmulsomes showed no significant
cytotoxicity until 24 hours, in contrast to free curcumin
which demonstrated significant toxicity especially in the
early stage, i.e. after 6 hours. Nonetheless, on the long
terms, incorporated curcumin preserved its biological ac-
tivity, and thus, acted as efficient as free curcumin. Ac-
cordingly, after 48 hours 30 μM CurcuEmulsome lowered
the viability of HepG2 to approximately 70%, 40 μM
CurcuEmulsome to approximately 50%, same percentages
as observed with free curcumin (Figure 6). In contrary,
empty emulsomes showed no significant effect on HepG2
cell viability.
It is also important to mention that the viabilities re-
corded over 100% (Figure 6) might be due to the phys-
ical interference of the CurcuEmulsomes (not supported
by our data since also the cells treated with curcumin at
low doses showed the same response), as well as due to
the changes in cellular activities involved in redox reac-
tions in response to curcumin and CurcuEmulsomes, as
Figure 5 Compositional analysis of CurcuEmulsomes. HPLC chromatograms show the compositional distribution of curcumin and its
analogues in (A) turmeric extract, (B) CurcuEmulsomes and (C) empty emulsomes. The HPLC data discloses that the composition of turmeric
inside the nanocarrier is different than the one fed to the system. The plane curve of empty emulsomes declines occurrence of any interference
of lipid composition of CurcuEmulsomes to the analysis.
Figure 6 Cell viability profile of HepG2 cells treated with curcumin and CurcuEmulsomes. Cytotoxicity of CurcuEmulsomes, as well as free
curcumin (in DMSO) and empty emulsomes, to HepG2 cells were investigated at various concentrations for 6, 24 and 48 hours compared to
untreated cells. Cell viabilities are given in percentages relative to untreated cells. n.s., not significant; **comparable after 48 hours.
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CellTiter-Blue is a fluorescent assay used to measure cell
viability via non-specific redox enzyme activity [34].
Therefore, although the latter hypothesis is likely to be
the case, the complete clarification merits further study.
Considering interference with cellular adhesion, curcumin
and CurcuEmulsomes caused also morphological changes in
HepG2 cells. Cells treated with free curcumin and CurcuE-
mulsomes showed a round shape whereas untreated cells
preserved their flattened morphology (Figure 7).
Uptake of CurcuEmulsomes by HepG2 cells
The uptake of CurcuEmulsomes in HepG2 cells could
be evaluated by fluorescence microscopy analysis by the
auto-fluorescence of curcumin (Figure 8). As previously
reported [19], the cellular uptake was observed to be
concentration-dependent as each increase in concentra-
tion from 10 μM to 50 μM resulted in an increase in
fluorescence intensity inside the cell (data not shown).
Along the time of treatment, fluorescence microscopy
analyses were performed sequentially after 6, 24 and
48 hours and information was collected regarding the
stepwise uptake mechanism and localization of curcu-
min and CurcuEmulsomes in HepG2. Accordingly, the
fluorescence signal was limited to the cellular membrane
for the first 6 hours, and widen to the inner compart-
ments of the cells after 24 hours (Figure 8A). In agree-
ment with Kunwar et al. (2008) [13], curcumin primarily
localized in the cell membrane and subsequently around
the nucleus, most likely due to their compartmental lipo-
philic properties. Moreover, in agreement with Mohanty
et al. (2010) [26], cells treated with free curcumin showed
the maximal fluorescence intensity at 24 hours, which
faded down significantly with time (Figure 8A). On the
contrary, cells treated with CurcuEmulsomes did not ex-
hibit any deterioration in the level of fluorescence inten-
sity neither after 24 nor 48 hours. This was attributed to
the enhanced stability as well as to the gradual release of
curcumin incorporated into the solid tripalmitin core of
the nanocarrier. Hence, encapsulated curcumin remained
protected from hydrolysis, and upon release, its biological
activity persisted alongside its fluorescence intensity for a
longer period of time than free curcumin.
Previous thin-sectioning analysis of HepG2 cells
treated with empty emulsomes demonstrated that emul-
somes are internalized in the cell within endosomes [30],
resulting in an accumulation of the nanocarrier inside
the cell before any sufficient release of the load could
occur. Confirming this, the present data verified accu-
mulation of CurcuEmulsomes inside the cytoplasm.
Highly fluorescent spherical regions were discovered in-
side the cells treated with CurcuEmulsomes, which are
ascribed to endosomes internalizing the nanocarriers. As
indicated by arrows (Figure 8B), these regions were only
detected for the cells exposed to CurcuEmulsomes for
24 and 48 hours. This finding may explain why CurcuE-
mulsome caused cytotoxicity first after 24 hours.
Effect of CurcuEmulsomes on cell cycle
To explore the physiological effect of CurcuEmulsomes
on cell proliferation, cell cycle analyses were performed
Figure 7 Effect of CurcuEmulsome on cell morphology.
(A) Untreated HepG2 cells preserved their flattened morphology
throughout the study, whereas cells treated with (B) curcumin or
(C) CurcuEmulsomes (both 30 μM) showed a round shape after
24 hours of exposure. Bars correspond to 50 μm.
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on stable HepG2 cells with and without free curcumin
or CurcuEmulsomes. Flow cytometry analysis demon-
strated that HepG2 cells exposed to free curcumin
(40 μM) for 24 hours were differentiated from untreated
ones with a higher populations in the G2/M phase (35%
instead of 18%) and with fewer fractions in the G0/G1
phase (55% instead of 71%; Figure 9). Compared to the
control, this result suggested that curcumin inhibited
the growth of HepG2 by causing cell-cycle arrest in the
G2/M phase. Remarkably, G2/M phase arrest declined
after reaching a peak at 24 hours indicating that there-
after free curcumin lost its activity and cells started re-
covery. On the contrary, CurcuEmulsome treatment at
40 μM resulted in a steady increase of cell population in
G2/M phase from 19% to 22% and then to 26%, as
population in G0/G1 phase decreases from 69% to 66%
and then to 64%, from 6 to 24 hours and subsequently
to 48 hours, respectively. At 48 hours, the cell cycle pro-
files of cells treated with curcumin and CurcuEmul-
somes became comparable: around 26% of the cells in
G2/M and 65% in G0/G1 phase (Figure 9). Cell cycle
profiles of untreated cells remained unaltered through-
out the experiment. Concisely, like free curcumin, Cur-
cuEmulsome induced G2/M cell cycle arrest on HepG2
cells, but this was prolonged probably since curcumin
was released inside the cell gradually over time.
Effect of CurcuEmulsomes on apoptosis
The apoptosis response of HepG2 to CurcuEmulsomes
and free curcumin was analyzed by a Caspase 3/7 activ-
ity assay in which higher fluorescence intensities corres-
pond to higher level of apoptosis. Like free curcumin,
CurcuEmulsomes caused a concentration-dependent in-
crease in apoptosis with comparable apoptotic activities
at 24 and 48 hours (Figure 10). These results strongly
suggested that the cytotoxicity of CurcuEmulsomes can
be attributed to the induction of apoptosis and G2/M
phase cell cycle arrest.
Discussion
The results of this study indicate that CurcuEmulsomes
can successfully entrap curcumin inside the inner solid
Figure 8 Cellular uptake of CurcuEmulsomes by HepG2 cells. (A) Cells were treated with 30 μM curcumin dissolved in DMSO, or
incorporated into CurcuEmulsomes in 10% FCS MEM medium for 6, 24 and 48 hours. (Bars correspond to 50 μm). (B) Inset image of cells treated
with CurcuEmulsomes (30 μM) for 48 h. Arrows indicate CurcuEmulsome accumulations upon cellular uptake. “N” indicates the cell nucleus. (Bar
corresponds to 10 μm).
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matrix composed of tripalmitin surrounded by phospho-
lipids. The stable formulations are spherical in shape and
preserve the surface characteristics of the nanocarrier.
Most important, the solubility of curcumin is increased up
to 0.11 mg/ml by means of CurcuEmulsomes, correspond-
ing to an improvement in solubility by 10,000 times. Thus
CurcuEmulsomes can achieve the effective concentrations
of curcumin (i.e. 10–50 μM) [25,26], and facilitate the de-
livery of bioactive molecules into the cell in vitro.
In the literature, various encapsulation approaches like
diblock copolymers [35,36], hydrophobically modified
starch [32], beta-casein micelles [37], lipid nanoemul-
sions [38], curcumin-rubusoside complexes [39], cyclo-
dextrin assemblies [40,41], liposomes [42], curcumin-
nanodisk [4] and polymeric NanoCurc™ formulations
[43] have been successfully applied to increase the solu-
bility and thereby the delivery of curcumin. Encapsula-
tion of curcumin in a pluronic block copolymer showed
not only anti-cancer activity comparable with free curcu-
min, but also demonstrated a slow and sustained release
of curcumin [36]. Therefore, the aforementioned ap-
proaches, as well as CurcuEmulsomes, look promising
to enable the effective use of curcumin in medical
applications.
However, having partially the characteristics of both lipo-
somes and emulsions, CurcuEmulsome approach possesses
certain advantages over its alternatives. Like liposomes,
emulsomes are stabilized by phospholipid (multi-)layers as
Figure 9 Flow cytometric DNA histograms of HepG2 cells. Effect of free curcumin and CurcuEmulsome on cell population of HepG2 cells
was investigated for 6, 24 and 48 hours after exposure. Like free curcumin, CurcuEmulsomes induce G2/M cell cycle arrest. However, the
expansion in population of cell at G2/M phase occurs after 48 hours, rather than 24 hours as for free curcumin. This delay is attributed to the
gradual release of curcumin from the solid tripalmitin core of the nanocarrier inside the cell. Cells are labeled with DAPI for detection with
Pacific Blue.
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outermost structure, and thus, there is no need for surfac-
tants stabilizing the nanoformulation. This endows emul-
somes high degree of biocompatibility at therapeutic
applications. More detailed, in the absence of any synthetic
surfactants such as poloxamers, polysorbates or doxycho-
late, the use of emulsomes as a drug delivery system has
demonstrable advantages, particularly for parenteral ad-
ministration of poorly water-soluble lipophilic drugs [27],
such as curcumin. Alternatively, due to their colloidal na-
ture, emulsomes can be passively taken up from the blood
stream by macrophages of the liver and spleen after intra-
venous or intracardiac administration as demonstrated in
early in vivo studies [44,45].
On the other hand, unlike lipid emulsions having a
fluid core, emulsomes with a solid fat core can prolong
the release of incorporated drugs - a property similar to
polymeric nanoparticles [28,46]. As previously demon-
strated, zidovudine-emulsome formulations displayed a
slow drug release profile in vivo (12–15% after 24 h) and
prolonged the action at comparatively low drug doses
[29]. Therefore, the developed CurcuEmulsomes would
be expected not only to circumvent the problems of low
solubility and rapid elimination, but also to modify the
drug release profile thereafter, due to the presence of
curcumin in the internal solid lipid core.
Finally, having an analogous surface as liposomes [47],
CurcuEmulsomes can further be tailored to fulfill specific
requirements such as longer blood circulation or to enable
cell targeting and active drug delivery. For instance, Gill
et al. (2011) coated emulsomes with O-palmitoyl amylo-
pectin [48], whereas Pal et al. (2012) coated them with
O-palmitoyl mannan both with the aim of developing
macrophage targeted systems [45]. In a recent study,
we showed that crystalline bacterial cell surface layer
(S-layer) proteins are capable to coat emulsomes and
modify their entire surface characteristics [30], e.g. by
altering zeta-potential.
The colloidal characteristics of the emulsome evidence
its robust character and indicate its potential in versatile
use for lipophilic therapeutic agents other than curcumin.
As previously reported [28-30], the size of emulsomes
(a mean diameter of 286 nm, Figure 3) is predomin-
antly determined by the phospholipid to tripalmitin ra-
tio, and evidently, incorporation of curcumin did not
influence neither particle size nor zeta potential char-
acteristics. Moreover, the particle sizes can be tuned by
altering the phospholipid to solid lipid ratio [29].
Although curcumin, DMC and BDMC show only very
small chemical modifications with respect to their num-
ber of methoxy groups, a decrease in hydrophobicity in
the order of curcumin > DMC > BDMC is known [49].
Therefore, a shift in the ratio of the analogues inside the
lipophilic fat core should be expected, but not in terms
of a relative decrease of curcumin compared to DMC
and BDMC (Figure 5). Hence, this result contradicts
with the relative hydrophobicity of the analogues, as well
as the findings of Rungphanichkul et al. (2011), where
encapsulation of curcuminoids in non-ionic surfactant
based liposomes, so-called niosomes, favored the incorp-
oration of curcumin rather than its analogues [50]. Al-
though some thermodynamic parameters such as the
polarity, as well as the molecular electrostatic interac-
tions of curcuminoids with charged groups of lipid com-
pounds, such as hexadecylamine, are thought to play a
role in this selective incorporation process, the complete
clarification of this finding merits further study.
Biological efficacy of CurcuEmulsomes was studied
in vitro on HepG2 cell line model. In line with earlier
Figure 10 Apoptotic activities of HepG2 cells treated with CurcuEmulsomes. Apoptosis responses of HepG2 cells to free curcumin and
CurcuEmulsomes were analyzed by a Caspase 3/7 activity assay. The level of fluorescence intensity corresponds to the level of apoptosis.
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studies on emulsomes [29], the delay in cytotoxicity is
attributed to the slow release of curcumin entrapped in-
side the solid core of emulsomes. Hence, on the short
terms the cytotoxic effect of CurcuEmulsomes remains
limited. Nevertheless, CurcuEmulsomes displayed pro-
longed biological activity and acted as efficiently as free
curcumin on long terms (Figure 6).
Like free curcumin, CurcuEmulsomes caused morpho-
logical changes in HepG2 cells where treated cells distin-
guished from untreated ones by their round shape.
Based on AFM studies, Jiang et al. (2012) demonstrated
the effect of curcumin on cytoskeletal arrangement of
HepG2 cells and, combined with flow cytometric ana-
lysis, correlated this morphological effect with the up-
regulated expression of tubulin [21]. The latter caused
disorganization of the well-organized, filamentous net-
work of healthy cells as deduced from the adopted
round shape. Therefore, delivering curcumin into the
cell, CurcuEmulsomes must be initiating the same effect
(Figure 7).
Indicating for an enhanced stability, fluorescence im-
ages demonstrated that incorporated curcumin preserve
its fluorescence intensity for longer times compared to
free curcumin (Figure 8A). Parallel to our previous
cross-sectional analysis of cells treated with empty emul-
somes [30], the fluorescence microscopic data verified
the accumulation of CurcuEmulsomes inside the cyto-
plasm upon their uptake by the cell (Figure 8B). Accord-
ingly, CurcuEmulsomes accumulate inside the cell before
any sufficient release of the load could occur. This finding
may explain why CurcuEmulsomes caused cytotoxicity
only after 24 hours (Figure 6).
Cell cycle analysis demonstrated that CurcuEmul-
somes cause a prolonged induction of G2/M cell cycle
arrest where the peak of G2/M phase rose steadily from
6 to 48 hours (Figure 9). In the contrary, free curcumin
results in a sharp increase after 24 hours which declined
after 48 hours. These findings, in line with cytotoxicity
data, corroborate the slow and sustained release of
curcumin from CurcuEmulsomes into the cells. Cell
cycle analyses were only performed for 48 hours be-
cause the low viability profiles of treated HepG2 cells
(Figure 6) did not allow longer investigations. How-
ever, speculatively, a further increase in G2/M phase
arrest might be predicted due to the slow release pro-
file of emulsomes.
Conclusions
Introducing a new nanocarrier system for curcumin, the
present study illustrates the particular characteristics of
CurcuEmulsomes and investigates the delivery of curcu-
min into the cell in vitro, where HepG2 cell line is used
as a model. In summary it may be concluded that i) cur-
cumin can be incorporated into the emulsomes, ii) the
incorporation enhances the poor water solubility of this
bioactive polyphenol, iii) upon incorporation, biological
activity as well as fluorescence integrity of curcumin is
preserved, iv) delivered within a solid lipid core, curcu-
min is gradually released into the cell, thereby resulting
in prolonged cytotoxicity and cell cycle arrest on HepG2,
v) due to its prolonged activity, the incorporated curcu-
min acts, on long terms, as efficient as free curcumin
dissolved in organic solvent. Consequently, enabling cur-
cumin to reach its effective concentrations inside the
cell, the presented approach may allow therapeutic ap-
plications of curcumin, and with future perspectives,
provide an alternative platform for the delivery of hydro-




Curcumin, glyceryl tripalmitate (tripalmitin, purity ≥99%),
1,2-dipalmitoyl-rac-glycero-3-phosphatidylcholine (DPPC,
99%), glutaraldehyde solution (50%), glycerol (99%) and
Dulbecco’s Phosphate Buffered Saline (PBS, 10X) were
purchased from Sigma-Aldrich GmbH, Germany. Hexa-
decylamine (HDA, ≥99%), uranyl acetate dehydrate
(≥98%), methanol (99.5%) and chloroform (≥99.8%)
were obtained from Fluka Chemika, Germany. Choles-
terol (>98%) was purchased from Avanti Polar-Lipids,
US. Dimethyl sulfoxide (DMSO) was purchased from
Riedel-de Haën (Sigma Aldrich, Germany). 4′,6-Diamidino-
2-phenylindole dihydrochloride (DAPI) was purchased from
AppliChem GmbH, Germany. All chemicals were used as
purchased without any further purification.
Cell line
HepG2 (human liver hepatocellular carcinoma cell line)
was obtained from American Type Culture Collection
(Rockville, MD; ATCC HB-8065). HepG2 cells were cul-
tured in Minimal Essential Medium (MEM) with Earlea’s
Salts medium (PAA, Pasching, Austria), supplemented
with 10% fetal calf serum (FCS) albumin and 1%
antibiotic/antimycotic (both PAA) at 37°C in a humidi-
fied atmosphere of 5% CO2 and 95% air.
CurcuEmulsome preparation
Curcumin and tripalmitin with a weight ratio of 2:5 were
dissolved in chloroform. DPPC, cholesterol and HDA
with a molar ratio of 10:5:4 were dissolved separately in
chloroform. Both lipid solutions were mixed and the or-
ganic solvent was completely removed using a rotary
evaporator (Rotavapor R-215, Büchi, Switzerland) under
reduced pressure at 474 mbar and 60°C. The formed dry
film was hydrated with MilliQ water, the temperature
was set to 80°C and the solution was rotated until the
lipid film was resuspended. The obtained product was
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homogenized by high pressure extrusion system with
heating control (Avestin Liposo Fast LF-50, Ottawa,
Canada). At a temperature of 66°C and under an over-
pressure above 10 bars, the solution was passed multiple
times through 800-nm and 400-nm polycarbonate filters
(Nucleopore Track-Etch Membrane, Whatman, UK).
Immediately after extrusion, the obtained emulsome
suspension was placed on ice for 10 min. CurcuEmul-
some preparations were centrifuged at 13,200 rpm
(16,100 g) for 10 minutes to spin down unincorporated
curcumin. The CurcuEmulsome suspension, i.e. the
supernatant, was stored at 4°C until further characterization
and cell culture studies. Empty emulsomes were prepared as
described above but without curcumin [30].
Quantification of curcumin by absorbance measurements
A 1 mg/ml stock solution of curcumin was prepared in
DMSO. A standard curve, generated by successive dilu-
tion of the stock solution (5, 10, 20, 50, 100 μg/ml) in a
96-well microplate (Cellstar, Greiner Bio-One GmbH,
Frickenhausen, Germany), was used to determine curcu-
min concentrations in samples prepared by dilution of
CurcuEmulsome suspension 1:10 in DMSO. Sample ab-
sorbance was measured at 430 nm on Infinite F200 plate
reader (TECAN, Austria).
Compositional analysis of CurcuEmulsomes
The composition of CurcuEmulsomes was determined
by HPLC. CurcuEmulsome formulation was dissolved in
methanol to disrupt its structure. The sample was sub-
jected to sonication for 3 min at 170 W (Transsonic T
460, Elma, Germany) followed by centrifugation at
14,680 rpm (20,238 g) for 10 min at 25°C (Centrifuge
5424, Eppendorf, Germany). The clear supernatant was
analyzed using reverse phase isocratic mode (RP-HPLC)
on Summit HPLC systems (Dixon/ThermoFisher Scien-
tific, Germany). In brief, 10 μl of the sample was injected
automatically in the injection port and analyzed on C18
column (Nucleosil 120-3C18, 150×4 mm, Macherey-
Nagel, Germany) with the mobile phase consisting of
acetonitrile and 2% acetic acid (40:60, v/v) at 33°C [51].
The amount of curcumin was quantified by UV detec-
tion at 420 nm with UV/VIS-Detector UVD 170U/340U
(Dionex, Germany). The compositional distribution of
curcumin in the sample was determined from the peak
area correlated with the standard curve. The total HPLC
analysis time was 20 min per sample, with curcumin,
DMC and BDMC eluting at retention times of 17.3, 15.4
and 13.7 min, respectively.
In vitro cytotoxicity assay
Cytotoxicity of CurcuEmulsomes was examined by
CellTiter-Blue Cell Viability Assay (Promega, Germany)
as described previously by Ucisik et al. (2013) [30].
Briefly, HepG2 cells were seeded in 96-well microtiter
plates at a density of 10,000 cells per well in a final vol-
ume of 300-μL culture medium. After 24 h, the cell cul-
ture media were aspirated and the cells were treated
with 100-μl culture medium containing free curcumin
(in DMSO) or CurcuEmulsomes at various concentra-
tions. Other cells were left untreated as negative control.
DMSO content in total cell medium was kept below
0.15% to avoid any influence of DMSO to HepG2.
Fluorescence intensity of cells was recorded using In-
finite F200 plate reader (TECAN, Austria) with a
560(20)Ex/595(35)Em fluorescence intensity filter (TECAN,
Austria).
Cell cycle analysis
HepG2 cells were seeded in cell culture flasks at a density
of 500,000 cells per 25 cm2. After two days of incubation
cell medium was changed with 5-ml culture medium con-
taining free curcumin (40 μM) or CurcuEmulsome
(40 μM). Other cells were left untreated as negative con-
trol. Cells were harvested, washed three times with PBS,
then counted and resuspended in PBS at concentration of
1×106 cells/ml. Of each sample 3×105 cells (300 μl) were
stained with 2 μg/ml DAPI in methanol for 15 min at
room temperature in the dark. Subsequently, cells were
centrifuged at 1250 rpm for 5 min, resuspended in ice-
cold FACS buffer (Becton Dickinson (BD), Austria) and
immediately analyzed via a FACSCanto II Flow Cytometer
equipped with a BD FACSDiva acquisition and analysis
program (BD, Austria). Samples, stained with DAPI, were
excited with a 405-nm blue laser and the emitted light in
the region of 450(50) nm (Pacific Blue) was recorded. Data
from at least 10,000 cell counts were collected for each
data file. Gating was set properly to exclude cell debris,
cell doublets, and cell clumps.
Apoptosis test
The apoptosis response of HepG2 cells to CurcuEmul-
somes and free curcumin in DMSO were analyzed by
Cell Meter Caspase 3/7 Activity Apoptosis Red Fluores-
cence Assay Kit (AAT Bioquest, Biomol, Germany). Briefly,
HepG2 cells were seeded in 96-well microtiter plates at a
density of 10,000 cells per well in a final volume of 100-μL
culture medium. After 24 h, the cell culture media were as-
pirated and the cells were treated with a medium contain-
ing free curcumin (in DMSO) or CurcuEmulsomes at
various concentrations for 6, 24 and 48 h. Other cells were
left untreated as negative control. At the time of analysis,
the medium was replaced and equal volume of Z-DEVD-
ProRed™ Reagent Assay was added to each well. Following
incubation of cells at room temperature for 70 min in the
dark, the fluorescence intensity at Ex/Em= 535(25)/635
(35) nm was monitored by Infinite F200 plate reader.
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Ultraviolet–visible (UV–vis) absorbance spectroscopy
UV–vis absorbance spectroscopy was performed on a
U-2900 UV/Vis spectrophotometer (Hitachi, Japan).
Samples were scanned from 300 to 700 nm.
Fluorescence spectroscopy
Fluorescence spectra were obtained on a Perkin Elmer
LS 55 luminescence spectrometer (Perkin Elmer, UK).
Curcumin samples were excited at 420 nm, and emission
was monitored from 430 to 600 nm (2.5-nm slit width).
Dynamic and phase analysis light scattering
Diluted in 1 mM KCl solution (pH 6.3) CurcuEmul-
somes with a final DPPC concentration of 4 μg/ml were
analyzed by the Zetasizer Nano ZS (Malvern Instruments
Ltd, UK) for their particle size distribution (Dynamic Light
Scattering; DLS) and zeta potential characteristics (Phase
Analysis Light Scattering; M3-PALS) as previously de-
scribed [30].
Electron microscopy
The shape and the integrity of CurcuEmulsomes were
analyzed by a FEI Tecnai G2 20 Transmission Electron
Microscope (TEM) at 120 kV equipped with FEI Eagle
4 k camera (FEI Europe, The Netherlands) after negative
staining with uranyl acetate (1% in MilliQ) as described
by Ucisik et al. (2013) [30].
Fluorescence microscopy
Nikon Eclipse TE2000-S fluorescence microscope (Nikon,
Melville, NY) was used to visualize the samples. The im-
ages of cell cultures were taken with 20× and 40× objec-
tives, and those of CurcuEmulsomes preparation with
100x oil immersion objective. Curcumin incorporated in
emulsomes was detected using a Cyan Fluorescent Protein
(CFP)-Fluorescence filter (Excitation at 436/20 nm; Emis-
sion at 480/40 nm).
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